【摘 要】
:
Active glutamine utilization is a major biochemical feature of most tumor cells and is fundamental for the survival and proliferation of tumor cells.Glutaminolysis represents the first and rate-limiti
【机 构】
:
Department of Biology College of Arts & Sciences, Department of Pathology & Lab.Medicine, College of
【出 处】
:
BITs 3rd Annual World Cancer Congress-2012(2012第五届世界癌症大会)
论文部分内容阅读
Active glutamine utilization is a major biochemical feature of most tumor cells and is fundamental for the survival and proliferation of tumor cells.Glutaminolysis represents the first and rate-limiting step of glutamine utilization,which is catalyzed by glutaminases.The oncogenic pathway activated by c-Myc has been reported to regulate glutamine utilization by increasing the expression of glutaminase and glutamine transporter.Whether other oncogenic signaling pathways promote glutamine utilization in tumors remains elusive.Breast cancer is the second most common cause of death for women in the United States and ErbB2 activation is one of the major causes of breast cancers.Using MCF 10A and MCF 10A-derived NeuT cells, we studied the effect of ErbB2 activation on glutaminase expression,and found that ErbB2 activation increased glutaminase 1 expression at both mRNA and protein levels.Knockdown of ErbB2 decreased glutaminase 1 expression in several human ErbB2-positive cell lines.In addition, blocking ErbB2 signaling pathway by trastuzumab reduced the expression levels of glutaminase 1.Importantly, ErbB2-mediated upregulation of glutaminase 1 was independent of c-Myc expression in MCF 10A cells.Activation of either PI3K/Akt or MAPK pathway was not sufficient to up-regulate glutaminase 1 expression;instead, inhibition of NF-κB pathway down-regulated glutaminase 1 expression whereas stimulation of NF-κB induced glutaminase 1 expression.Finally,inhibition of glutaminase activity significantly decreased human breast cancer cell proliferation.Taken together, our data indicate that ErbB2 activation promotes glutaminase 1 expression by PI3K/Akt-independent activation of NFκB in breast cancer cells, identifying another oncogenic pathway which stimulates glutamine utilization in tumor cells.These findings will facilitate the identification of novel targets for cancer diagnosis and treatment.
其他文献
The POU domain transcription factor Oct4 (POU5F1 or Oct3) is a member of the homeobox gene family and is specifically expressed in totipotent mouse and human embryonic stem (ES) and germ cells.It is c
In a single cell, the genome consists of individual DNA molecules of specific sequences.In cancers, genomic instability results in variations of DNA among cells originating from the same lineage.Singl
Soft tissue angiofibroma is a recently delineated tumor type of unknown cellular origin.Cytogenetic analysis of four cases showed that they shared a t(5;8)(p1 5;q1 3).In three of them it was the sole
DNMT methyltransferase 1 (DNMT1) plays a significant role in maintaining DNA methylation status.Aberrant DNA methylation is a recognized feature of human cancers, and folate is directly involved in DN
Activation of hypoxia signaling pathways is strongly associated with poor prognosis in cancer.Inactivation of the tumor suppressor gene encoding fumarate hydratase causes activation of hypoxia signali
Acacetin (5,7-dihydroxy-4-methoxyflavone), a flavonoid compound, has anti-peroxidative and anti-inflammatory effects.The effect of acacetin on antimetastasis in human prostate cancer DU-145 cells was
Over the years, our work has highlighted the critical role of an altered redox metabolism on cell survival and death signaling in cancer cells (Clement, M-V.and Pervaiz, S.2007).Using a variety of mod
Mitochondria are emerging as intriguing targets for anti-cancer agents.Vitamin E succinate (VES) has been shown to efficiently kill different types of cancer cells.A mitochondrially targeted analogue
In the upper aero-digestive tract mucosa, including the oral cavity, squamous cell carcinoma (SCC) represents 85-90% of malignant neoplasia.For decades there has been little improvement in patient pro
p53 is frequently mutated by genetic alternation or suppressed by various kinds of cellular signaling pathways in human cancers.Recently, we have revealed that p53 is suppressed and eliminated from ce